Not FDA-approved Brain & sleep

PT-141

PT-141 is a MC4R agonist. It is filed in this library under brain & sleep, a navigation topic rather than a statement of where it acts. As a regulatory matter it is not approved by the FDA for any use.

Regulatory status

PT-141 is not approved by the FDA for any use.

It is sold outside the approved-drug system, which means no regulator has reviewed its manufacturing, its purity or its effects.

From the FDA label

What PT-141 is approved to treat

is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. Limitations of Use VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

9 sources on PT-141 published between 2004 and 2024, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on brain & sleep

Start with your own numbers.

Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.

See the OPTML Score

Educational reference only. This page explains what has been published about PT-141. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides